FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SVLSF V, LLC 		2. Issuer Name and Ticker or Trading Symbol

Arsanis, Inc. [ ASNS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

ONE BOSTON PLACE, SUITE 3900, 201 WASHINGTON STREET 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/20/2017
(Street)

BOSTON, MA 02108
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/20/2017     C    19128   A   (1) 19128   D   (6)  
Common Stock   11/20/2017     C    404   A   (1) 19532   D   (7)  
Common Stock   11/20/2017     C    247010   A   (2) 266542   D   (6)  
Common Stock   11/20/2017     C    5219   A   (2) 271761   D   (7)  
Common Stock   11/20/2017     C    322102   A   (3) 593863   D   (6)  
Common Stock   11/20/2017     C    6806   A   (3) 600669   D   (7)  
Common Stock   11/20/2017     C    111955   A   (4) 712624   D   (6)  
Common Stock   11/20/2017     C    2365   A   (4) 714989   D   (7)  
Common Stock   11/20/2017     C    202915   A   (5) 917904   D   (6)  
Common Stock   11/20/2017     C    4288   A   (5) 922192   D   (7)  
Common Stock   11/20/2017     C    431980   A   (5) 1354172   D   (8)  
Common Stock   11/20/2017     C    14789   A   (5) 1368961   D   (9)  
Common Stock   11/20/2017     P    483448   A $10.00   1852409   D   (8)  
Common Stock   11/20/2017     P    16552   A $10.00   1868961   D   (9)  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A-1 Convertible Preferred Stock     (1) 11/20/2017     C         65287      (1)   (1) Common Stock   19128   $0.00   0   D   (6)  
Series A-1 Convertible Preferred Stock     (1) 11/20/2017     C         1380      (1)   (1) Common Stock   404   $0.00   0   D   (7)  
Series A-2 Convertible Preferred Stock     (2) 11/20/2017     C         690259      (2)   (2) Common Stock   247010   $0.00   0   D   (6)  
Series A-2 Convertible Preferred Stock     (2) 11/20/2017     C         14587      (2)   (2) Common Stock   5219   $0.00   0   D   (7)  
Series B Convertible Preferred Stock     (3) 11/20/2017     C         721402      (3)   (3) Common Stock   322102   $0.00   0   D   (6)  
Series B Convertible Preferred Stock     (3) 11/20/2017     C         15246      (3)   (3) Common Stock   6806   $0.00   0   D   (7)  
Series C Convertible Preferred Stock     (4) 11/20/2017     C         224665      (4)   (4) Common Stock   111955   $0.00   0   D   (6)  
Series C Convertible Preferred Stock     (4) 11/20/2017     C         4747      (4)   (4) Common Stock   2365   $0.00   0   D   (7)  
Series D Convertible Preferred Stock     (5) 11/20/2017     C         692552      (5)   (5) Common Stock   202915   $0.00   0   D   (6)  
Series D Convertible Preferred Stock     (5) 11/20/2017     C         14635      (5)   (5) Common Stock   4288   $0.00   0   D   (7)  
Series D Convertible Preferred Stock     (5) 11/20/2017     C         1474348      (5)   (5) Common Stock   431980   $0.00   0   D   (8)  
Series D Convertible Preferred Stock     (5) 11/20/2017     C         50477      (5)   (5) Common Stock   14789   $0.00   0   D   (9)  

Explanation of Responses:
(1)  The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
(2)  The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
(3)  The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
(4)  The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
(5)  The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
(6)  These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
(7)  These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
(8)  These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
(9)  These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SVLSF V, LLC
ONE BOSTON PLACE, SUITE 3900
201 WASHINGTON STREET
BOSTON, MA 02108
X

SV Life Sciences Fund VI Strategic Partners, L.P.
ONE BOSTON PLACE, SUITE 3900,
201 WASHINGTON STREET
BOSTON, MA 02108
X

SV Life Sciences Fund VI, L.P.
ONE BOSTON PLACE, SUITE 3900,
201 WASHINGTON STREET
BOSTON, MA 02108
X

SV Life Sciences Fund V Strategic Partners, L.P.
ONE BOSTON PLACE, SUITE 3900,
201 WASHINGTON STREET
BOSTON, MA 02108
X

SV LIFE SCIENCES FUND V LP
ONE BOSTON PLACE, SUITE 3900,
201 WASHINGTON STREET
BOSTON, MA 02108
X


Signatures
/s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund V, L.P. 11/20/2017
** Signature of Reporting Person Date

/s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund V Strategic Partners, L.P. 11/20/2017
** Signature of Reporting Person Date

/s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund VI, L.P. 11/20/2017
** Signature of Reporting Person Date

/s/ Mike Gray, as attorney-in-fact on behalf of SV Life Sciences Fund VI Strategic Partners, L.P 11/20/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Actelis Networks Charts.
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Actelis Networks Charts.